PE20200739A1 - Pirrolopirimidinas como potenciadores de cftr - Google Patents
Pirrolopirimidinas como potenciadores de cftrInfo
- Publication number
- PE20200739A1 PE20200739A1 PE2019001045A PE2019001045A PE20200739A1 PE 20200739 A1 PE20200739 A1 PE 20200739A1 PE 2019001045 A PE2019001045 A PE 2019001045A PE 2019001045 A PE2019001045 A PE 2019001045A PE 20200739 A1 PE20200739 A1 PE 20200739A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- alkyl
- cftr
- carbonitrile
- pyrrolo
- Prior art date
Links
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- IOWDAFLMNLDYIA-GFCCVEGCSA-N 4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-[(1R)-1-[1-(2-fluorophenyl)pyrazol-4-yl]ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)F)C#N)[C@H](C)C=1C=NN(C=1)C1=C(C=CC=C1)F IOWDAFLMNLDYIA-GFCCVEGCSA-N 0.000 abstract 1
- IOWDAFLMNLDYIA-LBPRGKRZSA-N 4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-[(1S)-1-[1-(2-fluorophenyl)pyrazol-4-yl]ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)F)C#N)[C@@H](C)C=1C=NN(C=1)C1=C(C=CC=C1)F IOWDAFLMNLDYIA-LBPRGKRZSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LSe refiere a un compuesto de formula (I) o una sal farmaceuticamente aceptable del mismo, en donde W es fenilo, que esta opcionalmente fusionado con un cicloalquilo de cinco a seis miembros o un heterocicloalquilo de cinco a seis miembros, entre otros; Y es un heteroarilo de cinco miembros que comprende uno, dos, tres o cuatro heteroatomos seleccionados del grupo que consiste en N, O y S(O)n; Z se selecciona del grupo que consiste en fenilo, alquilo C1-C6, cicloalquilo C3-C7, entre otros; R1a y R1b se seleccionan cada uno independientemente del grupo que consiste en -H, -OH, halo, alquilo C1-C6, entre otros; R2 se selecciona del grupo que consiste en -H, halo, -CN, entre otros; R3 y R4 se seleccionan del grupo que consiste en -H, alquilo C1-C6 y haloalquilo C1-C6. Son compuestos preferidos 4-amino-5-[2-(difluorometil)pirimidin-5-il]-7-{(1S)-1-[1-(2-fluorofenil)-1H-pirazol-4-il]etil}-7H-pirrolo[2,3-d]pirimidina-6-carbonitrilo, 4-amino-5-[2-(difluorometil)pirimidin-5-il]-7-{(1R)-1-[1-(2-fluorofenil)-1H-pirazol-4-il]etil}-7H-pirrolo[2,3-d]pirimidina-6-carbonitrilo, entre otros. Dichos compuestos son potenciadores del Regulador de Conductancia Transmembrana de la Fibrosis Quistica (CFTR), siendo utiles en el tratamiento de la fibrosis quistica, el asma, la bronquiectasia, la enfermedad pulmonar obstructiva cronica (EPOC). Tambien se refiere a composiciones farmaceuticas que comprenden dicho compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423919P | 2016-11-18 | 2016-11-18 | |
PCT/US2017/062148 WO2018094137A1 (en) | 2016-11-18 | 2017-11-17 | Pyrrolopyrimidines as cftr potentiators |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20200739A1 true PE20200739A1 (es) | 2020-07-24 |
Family
ID=62144793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019001045A PE20200739A1 (es) | 2016-11-18 | 2017-11-17 | Pirrolopirimidinas como potenciadores de cftr |
Country Status (21)
Country | Link |
---|---|
US (5) | US10301315B2 (es) |
EP (1) | EP3541390B1 (es) |
JP (3) | JP6978507B2 (es) |
KR (2) | KR102585398B1 (es) |
CN (2) | CN110337294B (es) |
AU (2) | AU2017362350B2 (es) |
BR (1) | BR112019010167A2 (es) |
CA (1) | CA3044050A1 (es) |
CL (1) | CL2019001334A1 (es) |
CO (1) | CO2019005993A2 (es) |
CR (1) | CR20190292A (es) |
DO (1) | DOP2019000126A (es) |
EC (1) | ECSP19043120A (es) |
IL (2) | IL296279A (es) |
MX (2) | MX2019005822A (es) |
PE (1) | PE20200739A1 (es) |
PH (1) | PH12019501098A1 (es) |
RU (2) | RU2757457C2 (es) |
SG (1) | SG10202106949XA (es) |
UA (1) | UA125400C2 (es) |
WO (1) | WO2018094137A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3698782A1 (en) | 2012-01-06 | 2020-08-26 | Lundbeck La Jolla Research Center, Inc. | Carbamate compounds for use in therapy |
MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
CA3009339A1 (en) * | 2015-12-22 | 2017-06-29 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
RS62670B1 (sr) | 2016-09-30 | 2021-12-31 | Vertex Pharma | Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora |
US10301315B2 (en) * | 2016-11-18 | 2019-05-28 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrrolopyrimidines as CFTR potentiators |
JOP20190125B1 (ar) | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
CN110300589B (zh) | 2016-12-16 | 2023-03-10 | 囊性纤维化基金会 | 作为cftr增效剂的双环异杂芳基衍生物 |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
KR102606188B1 (ko) | 2017-08-02 | 2023-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 피롤리딘 화합물을 제조하기 위한 공정 |
CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
ES2939775T3 (es) | 2018-02-15 | 2023-04-26 | Vertex Pharma | Macrociclos como moduladores del regulador de la conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de los mismos, su uso en el tratamiento de la fibrosis quística, y procesos para elaborarlos |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
MX2021015133A (es) * | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
CA3143431A1 (en) | 2019-07-15 | 2021-01-21 | Novartis Ag | Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
AU2020328028A1 (en) | 2019-08-14 | 2022-03-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
CN111138439B (zh) * | 2020-01-17 | 2021-06-25 | 厦门大学 | 氟代吡咯并嘧啶类化合物及其制备方法和应用 |
US20230192700A1 (en) | 2020-03-06 | 2023-06-22 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
MX2023001993A (es) | 2020-08-20 | 2023-02-27 | Univ Leland Stanford Junior | Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad. |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ258690A (en) * | 1992-12-17 | 1997-01-29 | Pfizer | Pyrrolopyrimidines and pharmaceutical compositions containing such compounds; intermediate pyrrole compounds |
IL149462A0 (en) * | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
US20030208067A1 (en) * | 2001-05-30 | 2003-11-06 | Cao Sheldon Xiaodong | Inhibitors of protein kinase for the treatment of disease |
US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
JP5512975B2 (ja) * | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬 |
WO2007104944A1 (en) * | 2006-03-11 | 2007-09-20 | Vernalis (R & D) Ltd. | Pyrrolopyrimidine derivatives used as hsp90 inhibitors |
AU2007347115A1 (en) * | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
BRPI0820342A2 (pt) * | 2007-11-07 | 2015-05-26 | Foldrx Pharmaceuticals Inc | Modulação de tráfego de proteína |
EA024252B1 (ru) * | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
WO2013071232A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
WO2015091532A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Pyrrolopyrimidine derivatives as pi3k inhibitors |
US10301315B2 (en) * | 2016-11-18 | 2019-05-28 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrrolopyrimidines as CFTR potentiators |
-
2017
- 2017-11-17 US US15/815,809 patent/US10301315B2/en active Active
- 2017-11-17 AU AU2017362350A patent/AU2017362350B2/en active Active
- 2017-11-17 CA CA3044050A patent/CA3044050A1/en active Pending
- 2017-11-17 CR CR20190292A patent/CR20190292A/es unknown
- 2017-11-17 IL IL296279A patent/IL296279A/en unknown
- 2017-11-17 KR KR1020197017510A patent/KR102585398B1/ko active IP Right Grant
- 2017-11-17 BR BR112019010167A patent/BR112019010167A2/pt active Search and Examination
- 2017-11-17 CN CN201780083801.0A patent/CN110337294B/zh active Active
- 2017-11-17 MX MX2019005822A patent/MX2019005822A/es unknown
- 2017-11-17 RU RU2019118623A patent/RU2757457C2/ru active
- 2017-11-17 SG SG10202106949XA patent/SG10202106949XA/en unknown
- 2017-11-17 MX MX2021012639A patent/MX2021012639A/es unknown
- 2017-11-17 JP JP2019547579A patent/JP6978507B2/ja active Active
- 2017-11-17 WO PCT/US2017/062148 patent/WO2018094137A1/en active Application Filing
- 2017-11-17 KR KR1020237033420A patent/KR20230146104A/ko active Application Filing
- 2017-11-17 PE PE2019001045A patent/PE20200739A1/es unknown
- 2017-11-17 CN CN202211239693.0A patent/CN115850268A/zh active Pending
- 2017-11-17 RU RU2021129721A patent/RU2021129721A/ru unknown
- 2017-11-17 EP EP17872726.9A patent/EP3541390B1/en active Active
- 2017-11-17 UA UAA201906838A patent/UA125400C2/uk unknown
-
2019
- 2019-04-05 US US16/377,005 patent/US10494374B2/en active Active
- 2019-05-15 IL IL266668A patent/IL266668B2/en unknown
- 2019-05-16 CL CL2019001334A patent/CL2019001334A1/es unknown
- 2019-05-16 PH PH12019501098A patent/PH12019501098A1/en unknown
- 2019-05-17 DO DO2019000126A patent/DOP2019000126A/es unknown
- 2019-06-07 CO CONC2019/0005993A patent/CO2019005993A2/es unknown
- 2019-06-17 EC ECSENADI201943120A patent/ECSP19043120A/es unknown
- 2019-09-20 US US16/578,277 patent/US20200017512A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,062 patent/US20210171534A1/en not_active Abandoned
- 2021-11-10 JP JP2021183048A patent/JP7360434B2/ja active Active
-
2022
- 2022-03-16 AU AU2022201816A patent/AU2022201816B2/en active Active
-
2023
- 2023-04-13 US US18/134,455 patent/US20230250100A1/en active Pending
- 2023-09-29 JP JP2023169299A patent/JP2023182694A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20200739A1 (es) | Pirrolopirimidinas como potenciadores de cftr | |
ECSP18032223A (es) | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO DE USO | |
CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
CO2017005421A2 (es) | Cromanos sustituidos y métodos para su uso | |
DOP2018000020A (es) | Tricíclicos sustituidos y método para usarlos | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
NI201400151A (es) | 7H - PIRROLO [ 2, 3 - d ] PIRIMIDINAS 4 - ( AMINO - SUBSTITUIDAS ) NOVEDOSAS COMO INHIBIDORES DE LRRK2. | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
CL2018003060A1 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
PE20160869A1 (es) | Derivados novedosos de amino pirimidina | |
EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
CL2013002877A1 (es) | Compuestos derivados de 2-aminopirimidina o una de sus sales, tautomeros o solvatos farmaceuticamente aceptables, moduladores de los receptores tlr7 y/o tlr8; composicion farmaceutica que los comprende, utiles para el tratamiento de infecciones viricas tales como vhb o vhc | |
EA201691484A1 (ru) | Соли и твердая форма ингибитора btk | |
PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
CO2019004190A2 (es) | Formulaciones liposomales para uso en el tratamiento del cáncer | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы |